PropertyValue
?:abstract
  • Objectives: To evaluate the efficacy of TruScreen (TS01) for high-risk human papillomavirus (HR-HPV) women compared with other methods in reducing colposcopy referral rates in hospitals. Methods: A single-center, prospective, case-control study was conducted from December 2019 to June 2020. Results: Among 139 (46.2%) HR-HPV positive patients, 58 were CIN1, 52 were CIN2-3 and 29 had cervical cancer (n = 29). The sensitivity and specificity of detecting CIN2+ by TS01, colposcopy and HPV16/18 testing were 96.3% and 46.4%, 85.2% and 40.5% and 59.3% and 74.1%, respectively. The highest sensitivity was 96.3% at HPV16/18 and TS01 (each positive results), and the highest specificity was 83.6% at HPV16/18 and TS01 (both positive) for CIN2+ compared with the other methods. Conclusion: TS01 is a noninvasive screening method and can be used to diagnose cervical lesions quickly. It is especially suitable as triage tool for HR-HPV-positive women facing SARS-Cov-2 exposure and infection risks in hospital.
is ?:annotates of
?:creator
?:journal
  • Future_oncol
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • TruScreen detection of cervical tissues for high-risk human papillomavirus-infected women during the coronavirus disease 2019 pandemic
?:type
?:who_covidence_id
  • #983820
?:year
  • 2020

Metadata

Anon_0  
expand all